Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy
NCT ID: NCT01255774
Last Updated: 2011-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
20 participants
INTERVENTIONAL
2007-06-30
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ranibizumab
Open Label use of Ranibizumab for wet age related macular degeneration
ranibizumab
An open-label, study of intravitreally administered ranibizumab
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ranibizumab
An open-label, study of intravitreally administered ranibizumab
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects of either gender, Age \> 50 years
* Best corrected visual acuity in the study eye between 20/40 and 20/320.
* Subfoveal choroidal neovascularization, secondary to age related macular degeneration.
* Any subretinal hemorrhage must comprise no more than 50% of total lesion size.
* Clear ocular media and adequate papillary dilation to permit good quality stereoscopic fundus photography
* Men must use barrier contraception or abstinence throughout the study.
* Ability to return for all study visits
Exclusion Criteria
* Had previous refractive eye surgery (RK, PRK, LASIK, ALK, etc.) within the past 3 months for the study eye.
* Has intraocular pressure ≥ 25 mmHg in the study eye.
* Has posterior uveitis in the study eye.
* Has ongoing infection in the study eye.
* Has retinal or optic nerve disease that could independently affect visual acuity including high axial myopia (\>-8.00 D) and diabetic retinopathy in the study eye.
* Has anterior segment and vitreous abnormalities that would preclude adequate observation of the fundus for photographs and fluorescein angiography in the study eye.
* Has received investigational therapy within 60 days prior to study entry.
* Has been previously enrolled in or previous treatment with MSI-1256F for injection.
* Has received prior approved treatment for subfoveal CNV within 60 days to study entry.
* Has clinically uncontrolled diabetes mellitus.
* Has other condition the investigator considers to be sound reasons for exclusion (e.g., lack of motivation, history of poor compliance, concomitant illnesses, personality disorder, mental condition, drug abuse, use of neuroleptics, physical or social condition predicting difficulty in long-term follow-up).
* Has an allergy to sodium fluorescein dye.
* Currently uses systemic or topical medications known to be toxic to the retina, lens, or optic nerve, such as deferoxamine, chloroquine/hydrochloroquine, tamoxifen, chlorpromazine, phenothiazines, steroids and ethambutol.
* Pregnancy (positive pregnancy test) or lactation
* Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.
51 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genentech, Inc.
INDUSTRY
The New York Eye & Ear Infirmary
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
New York Eye and Ear Infirmary
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Richard B Rosen, MD
Role: PRINCIPAL_INVESTIGATOR
New York Eye and Ear Infirmary
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New York Eye and Ear Infirmary
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Katy W Tai, CCRC
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NYEE-07.14
Identifier Type: -
Identifier Source: org_study_id